Amyris Inc (AMRS) Insider John Melo Sells 5,195 Shares of Stock

Amyris Inc (NASDAQ:AMRS) insider John Melo sold 5,195 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $7.50, for a total transaction of $38,962.50. Following the sale, the insider now directly owns 743,713 shares of the company’s stock, valued at approximately $5,577,847.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of AMRS stock opened at $7.37 on Thursday. Amyris Inc has a 12-month low of $2.82 and a 12-month high of $9.28. The company has a debt-to-equity ratio of -0.24, a quick ratio of 0.38 and a current ratio of 0.42. The company has a market capitalization of $508.54 million, a P/E ratio of -2.42 and a beta of 0.26.

Amyris (NASDAQ:AMRS) last issued its earnings results on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). The company had revenue of $24.81 million for the quarter, compared to the consensus estimate of $37.52 million. During the same quarter in the prior year, the company earned ($1.32) EPS. The company’s revenue was down 3.4% compared to the same quarter last year. As a group, equities analysts predict that Amyris Inc will post -1.41 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Amyris in the first quarter worth approximately $110,000. B. Riley Financial Inc. boosted its holdings in Amyris by 80.0% in the second quarter. B. Riley Financial Inc. now owns 79,219 shares of the biotechnology company’s stock worth $508,000 after purchasing an additional 35,219 shares during the last quarter. Ardsley Advisory Partners boosted its holdings in Amyris by 25.0% in the second quarter. Ardsley Advisory Partners now owns 125,000 shares of the biotechnology company’s stock worth $799,000 after purchasing an additional 25,000 shares during the last quarter. Millennium Management LLC purchased a new stake in Amyris in the first quarter worth approximately $1,643,000. Finally, Barclays PLC boosted its holdings in Amyris by 30,067.8% in the first quarter. Barclays PLC now owns 44,950 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 44,801 shares during the last quarter. Institutional investors own 27.90% of the company’s stock.

Several equities research analysts recently weighed in on the stock. BidaskClub downgraded shares of Amyris from a “buy” rating to a “hold” rating in a research report on Saturday, October 13th. Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. B. Riley set a $10.00 price target on shares of Amyris and gave the company a “buy” rating in a research report on Wednesday, October 3rd. Finally, HC Wainwright set a $15.00 price target on shares of Amyris and gave the company a “buy” rating in a research report on Thursday, October 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Amyris presently has a consensus rating of “Buy” and a consensus target price of $9.13.

About Amyris

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Read More: Why is the ex-dividend date different from the record date?

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply